← Eichor
Study identifier: NCT03718923 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Condition: FOXP1 · Mental Retardation With Language Impairment and With or Without Autistic Features · Autism Spectrum Disorder  ·  Sponsor: Icahn School of Medicine at Mount Sinai

PhaseN/A
Planned participants50
Who can joinAll sexes, 2 Years to no upper limit
Healthy volunteersNo

About this study

FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

This description comes directly from the study's public registry record.

Talk to the study team

Hailey Silver  ·  (212) 241- 6231  ·  hailey.silver@mssm.edu

Tess Levy  ·  212-241-5290  ·  tess.levy@mssm.edu

Always discuss trial participation with your own doctor first.

Locations (1)

The Seaver Autism Center for Research and TreatmentNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03718923